CRSP vs TECH · rev $37.3M vs P/E 65, rev $1.22B
Crispr Therapeutics AG (CRSP) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported CRSP revenue for 2024-12-31 was $37.3M. Net income was -$366.3M. Revenue was down 89.9% from 2023-12-31 to 2024-12-31. CRSP currently screens at market cap $5.42B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
CRSP currently screens at market cap $5.42B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the CRSP and TECH stock pages for the full models.
Not investment advice.